BioSpace News Archive

Sigilon Therapeutics delivered an oral presentation featuring data on its hemophilia A program at the American Society of Gene and Cell Therapy Annual Meeting in Washington, D.C. The data presented will support the company’s planned regulatory filing of SIG-001 later this year to enable initiation of clinical trials.

Allogeneic “off the shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome significant challenges of current autologous CAR-T therapies

State of Hearing Report highlights the physical, emotional and societal challenges of hearing loss

Purchase of leading Just-In-Time clinical trials recruitment service will benefit patients, physicians and drug developers by connecting cancer patients to the right trials faster

Reports revenue growth of 7% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic

Shareholders Approved All Allergan Proposals and Voted AGAINST Shareholder Proposal Calling for Immediate Separation of Chairman and CEO Role

2019 EPS Guidance Raised And Narrowed To Reflect Strong Performance Year-to-Date

Sensient Technologies Corporation reported earnings per share of 78 cents in the first quarter of 2019 compared to 89 cents in last year’s first quarter.

A study based on a multi-year survey of 6,200 specialists released by the Royal College of Physicians and Surgeons of Canada revealed the highest percentage of reported employment challenges since the launch of the Royal College Employment Survey in 2011.

Precision Protein® marks the beginning of a new era in whey-protein formulation and supplementation.